Lugui Qiu, MD

Professor & Director, Department of Lymphoma & Myeloma
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, China (People's Republic)

n/a

Poster(s):

• 1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

• 1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia

• 2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

• 2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database